A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

2009435 citationsJournal Articlehybrid Open Access

Authors

Hideki Ueno

T Kosuge

Y Matsuyama

Junji Yamamoto · The Cancer Institute Hospital

Akimasa Nakao · Nagoya University

Shinichi Egawa · Tohoku University Hospital

Ryuichiro Doi · Kyoto University

Morito Monden · Osaka University

Abstract

The current results suggest that adjuvant gemcitabine contributes to prolonged DFS in patients undergoing macroscopically curative resection of pancreatic cancer.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Pancreatitis Pathology and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 101, Issue 6, pp. 908-915

DOI: 10.1038/sj.bjc.6605256

Field-Weighted Citation Impact: 11.22